Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).
EP. 1: The Burden of ASCVD and Evidence-Based Guidelines
Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.
EP. 2: A Patient’s Post-MI Journey
Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.
EP. 3: Improving the Care Continuum
An expert advises how to optimize the care continuum for patients with ASCVD.
EP. 4: Residual Cardiovascular Risk
Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.
EP. 5: Who is an Ideal Patient for Early Intensive Lipid Lowering?
Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.
EP. 6: Finding the Optimal Statin Dose
Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.
EP. 7: Therapy Beyond Statins in the Inpatient Setting
Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.
EP. 8: Using Adjunct Therapies in LDL Management
Dr Brinton highlights the importance of adjunct therapies in LDL management.
EP. 9: Ensuring Continuity of Care for the ASCVD Patient
Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.
EP. 10: Unmet Needs in Lipid Management
Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.
EP. 11: Defining “Optimal Care” for ASCVD Within Health Systems
Drs Riddock and Slipczuk define “optimal care” for ASCVD from a system-level perspective with the use of quality metrics.
EP. 12: What Does a Multidisciplinary Team Look Like?
Drs Brinton and Slipczuk go into detail regarding an ideal multidisciplinary team for ASCVD treatment.
EP. 13: The Future of LDL Management for Patients With High-Risk ASCVD
Three cardiovascular experts discuss the future of lipid management for patients with high-risk ASCVD.
EP. 14: Enhancing Patient Care Through Guideline Adherence
Dr Leandro N. Slipczuk highlights the importance of cardiovascular treatment guidelines when deciding on patient care for those with ASCVD.
EP. 15: Improving Access to PCSK9 Inhibitors in the Inpatient Setting
Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.
EP. 16: Appropriate ASCVD Treatment Outside of Closed Health Systems
Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.
EP. 17: Utilizing Quality Metrics in ASCVD
Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.
EP. 18: Improving Patient and Provider Engagement
A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.
EP. 19: Treatment Disparities in the Management of ASCVD
Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.
2 Clarke Drive Cranbury, NJ 08512